Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials

The randomized, double‐blind, cardiovascular outcomes trials LEADER (NCT01179048) and SUSTAIN 6 (NCT01720446) showed cardiovascular risk reduction in patients with type 2 diabetes treated with liraglutide and semaglutide, respectively, compared with placebo. This post hoc analysis examined the impac...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Obes Metab
Hlavní autoři: Verma, Subodh, Bain, Stephen C., Honoré, Julie Broe, F. E. Mann, Johannes, A. Nauck, Michael, E. Pratley, Richard, Rasmussen, Søren, Sejersten Ripa, Maria, Zinman, Bernard, Buse, John B.
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2020
Témata:
Brief Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7689837/
https://ncbi.nlm.nih.gov/pubmed/32643857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14140
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky